Exchange: NASDAQ·Updated 09:49 AM EDT
News
all
press releases
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
Zacks
More News
Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday
Zentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Grows By 22.2%
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,204,555...
MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given an average rating of "Hold" by the seven brokerages that are presently covering the company, Marketbeat reports. One...
MarketBeat
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 31.4% during the third quarter, according to its most recent filing with the Securities...
MarketBeat
Pharmaceutical Stocks To Follow Today - April 10th
Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...
MarketBeat
What's Behind The Surge In Zentalis Stock?
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.read more...
Benzinga
This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally
Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.
Stocktwits
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00
Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday...
MarketBeat
These Stocks are Heating Up Fast
Top stocks to trade this afternoon. $ONCO, $KBLB, $ARAI, $EOSE, $ZNTL
24-7 Market News

Advertisement|Remove ads.